CatalystWireBeta

UK small-cap RNS · 8 Dec 2025

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.

Sort: Newest · Largest companies
  1. 16:30
    Holding(s) in Company Holding
  2. 11:50
    Tulu Kapi Project Finance and Launch Update
    · As per the Company's announcement of 20 October 2025, of the total Project funding requirement of US$340 million:
    Project milestones outlook positive +2.1% on the day
    Moved: Tulu Kapi project financing and construction: Debt approved; equity oversubscribed; closing pending → Debt documented; equity-risk gap partly covered by term sheets
  3. 07:00
    Successful FDA Meeting; IPF Phase 3 in 1H26
    PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
    Disposal of a part (break-up) outlook positive +1.5% on the day
    Moved: Meet FDA on deupirfenidone Phase 3 design by end of Q3 2025: pending → delivered – The End-of-Phase 2 meeting with the FDA on the deupirfenidone Phase 3 design has been completed, though the announcement is dated after the Q3 2025 deadline. · Initiate Phase 3 deupirfenidone IPF trial (end-2025, then H1 2026, then early Q3: pending → on_track – Phase 3 SURPASS-IPF start is guided for H1 2026, within the existing window (dossier deadline is early Q3 2026). · Close Celea financing by H1 2026 (originally early 2026): pending → on_track – Celea expects to finalize financing in early 2026, within the H1 2026 deadline, to support the Phase 3 start.
  4. 07:00
    Imminent contract award
    A Notice of Intent to Award for two 8116 cameras at a Pacific Northwest airport is a small first step toward the several year-end awards flagged at interims, easing cash pressure. Contract value is not stated and the award is not yet final.
    Moved: Going concern and cash runway: Cash £1.65m; orders needed to avoid fundraise → First year-end order notice received; value unstated
  5. 07:00
    Private Placement in UK and Norway
    Raises about £3.66m through UK and Norwegian placings at a 10% discount, issuing 100.9m new shares. The CEO concedes 'painful dilution', but the money funds uranium permits, Puglia solar construction and ICSID legal costs.
    Project milestones £3.7m · 13% of mcapoutlook positive −15.2% on the day
    Moved: new: Dilutive placing to fund projects – Completed; UK shares admit around 16 December · Tunisian authorities dispute and oil confiscation: Unauthorised sale; legal remedies being pursued → ICSID arbitration; legal team expanded · Italian uranium exploration permits: Applications accepted by Lombardy; EIA being prepared → Applications accepted; EIAs being prepared; funded

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note